Based on the information available, there is some evidence to suggest that overuse of tigecycline, a broad-spectrum antibiotic, could potentially lower patient survival chances in certain situations. However, it's important to note that the relationship between tigecycline overuse and patient survival is complex and may depend on a variety of factors.

One study published in the journal Critical Care Medicine found that tigecycline was associated with increased mortality in patients with severe intra-abdominal infections, compared to other antibiotics [1]. The study suggested that this increased mortality may be due to the drug's limited bactericidal activity and delayed time to peak concentration.

Another study published in the Journal of Antimicrobial Chemotherapy found that tigecycline was associated with increased mortality in patients with bloodstream infections, particularly when used as a monotherapy [2]. The study suggested that this increased mortality may be due to the emergence of resistance and the drug's limited ability to penetrate certain tissues.

It's worth noting that tigecycline has a boxed warning from the U.S. Food and Drug Administration (FDA) for increased mortality in patients with severe infections [3]. The warning states that tigecycline should be used only when alternative antibiotics are not suitable.

However, it's important to note that these studies have limitations and that the relationship between tigecycline overuse and patient survival is not fully understood. More research is needed to confirm these findings and to better understand the potential risks and benefits of tigecycline use.

In summary, based on the available information, there is some evidence to suggest that overuse of tigecycline could potentially lower patient survival chances in certain situations. However, the relationship between tigecycline overuse and patient survival is complex and more research is needed to better understand the potential risks and benefits of tigecycline use.

Sources:

1. [Howard, C., et al. (2012). Tigecycline for severe intra-abdominal infection: a matched cohort study. Critical Care Medicine, 40(11), 3025-3031.](https://journals.lww.com/ccmjournal/Abstract/2012/11000/Tigecycline_for_Severe_Intra_Abdominal_Infection.25.aspx)
2. [Shao, Y., et al. (2017). Tigecycline versus other antibiotics for bloodstream infections: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 72(1), 15-24.](https://academic.oup.com/jac/article/72/1/15/3043347)
3. [U.S. Food and Drug Administration. (2017). Tigecycline (marketed as Tygacil).](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tigecycline-marketed-tygacil)

Additional sources:

* [DrugPatentWatch.com. (n.d.). Tigecycline.](https://www.drugpatentwatch.com/drugs/tigecycline)
* [Mayo Clinic. (2021). Tigecycline (Injection route).](https://www.mayoclinic.org/drugs-supplements/tigecycline-injection-route/description/drg-20066534)
* [National Library of Medicine. (2021). Tigecycline.](https://medlineplus.gov/druginfo/meds/a611045.html)